915 abstracts found.



Results filter

Inter-lesional variability of DCE-MRI response and changes in cardiac output following infusion of the vascular disruptive agent Combretastatin-A4-Phosphate (CA4P)

Year:

Session type:

Andrew Gaya1, N. Jane Taylor2, Tarun Mittal3, J James Stirling2, James d'Arcy4, D Koh4, Gordon Rustin1, Tim Meyer5, Paul Nathan1, David Collins4, Anwar Padhani2

1Mount Vernon Hospital, Northwood, Middlesex, UK, 2Paul Strickland Scanner Centre, Northwood, Middlesex, UK, 3Dept. Imaging, Harefield Hospital, Harefield, Middlesex, UK, 4CR-UK Imaging Group, Institute of Cancer Research, Sutton, Surrey, UK, 5Dept Medical Oncology, Royal Free Hospital, London,, UK


Developing new PET tracers and studying them with new techniques

Year:

Session type:

Martin Christlieb, Robert King

University of Oxford, Oxford, UK


Gene expression following ionising radiation: Identification of biomarkers for dose estimation and prediction of individual response

Year:

Session type:

Sylwia Dziwura1, Alan Mackay2, Paul Finnon1, Simon Bouffler1, Christophe Badie1

1Health Protection Agency, Chilton, Didcot, Oxfordshire, UK, 2The breakthrough Breast Cancer Research centre at the Institute of Cancer Research, London, UK


Temporal evolution and duration of anti-vascular properties of bevacizumab in metastatic colorectal carcinoma (CRC): evaluation by DCE-MRI and tumour volumetrics

Year:

Session type:

James O'Connor1, Geoff Parker1, Andrew Clamp2, Alan Jackson1, Chris Rose1, Claire Mitchell2, Yvonne Watson1, Sue Cheung1, Giovanni Buonaccorsi1, Lynn Hope2, Paula Thorton2, Caleb Roberts1, Olivia del Puerto3, Jurgees Hasan2, Gordon Jayson2

1Imaging Science and Biomedical Engineering, University of Manchester, Manchester, UK, 2CR-UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK, 3Roche Products Limited, Welwyn Garden City, UK


Abstract withdrawn

Year:

Session type:


Imaging tumour pH and carbonic anhydrase activity using magnetic resonance imaging

Year:

Session type:

Ferdia Gallagher1, Mikko Kettunen1, Sam Day1, Rebekah McLaughlin1, De-En Hu1, Jan Ardenkjær-Larsen4, Rene in ‘t Zandt5, Pernille Jensen5, Magnus Karlsson5, Klaes Golman5, Mathilde Lerche5, Kevin Brindle1

1Cancer Research UK, Cambridge Research Institute, Cambridge, UK, 2Department of Biochemistry, University of Cambridge, Cambridge, UK, 3Department of Radiology, University of Cambridge and Addenbrooke's Hospital, Cambridge, UK, 4GE Healthcare, Amersham, UK, 5Imagnia AB, Malmo, Sweden


Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo

Year:

Session type:

Tiernan Byrnes1, Thomas Barrick1, Anthony Bell1, Chris Clark2

1St. George's, Univeristy of London, London, UK, 2UCL Institute of Child Health, London, UK


Palliative external beam radiotherapy to the oesophagus – a single centre evaluation

Year:

Session type:

VS Kumar1, OS Din2, JC Wadsley1

1Dept of Clinical Oncology, Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, UK, 2Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, South Yorkshire, UK


Results of the radiotherapy comparison within BC2001 – a phase III randomised trial of standard versus reduced volume radiotherapy with or without synchronous chemotherapy in muscle invasive bladder cancer

Year:

Session type:

Robert Huddart1, Emma Hall2, Nicholas James3, Sayed Hussain3, Malcolm Crundwell4, Jean Tremlett5, Peter Jenkins6, Christine Rawlings7, Shaun Rogers2

1The Institute of Cancer Research, Clinical Academic Radiotherapy, Sutton, UK, 2The Institute of Cancer Research, Clincal Trials and Statistics Unit, Sutton, UK, 3University of Birmingham, CR-UK Institute for Cancer Studies, Birmingham, UK, 4Royal Devon and Exeter Hospital NHS Foundation Trust, Department of Urology, Exeter, UK, 5Sussex Cancer Centre, Department of Radiotherapy, Brighton, UK, 6Cheltenham General Hospital, Gloucestershire Oncology Centre, Cheltenham, UK, 7South Devon Healthcare Trust, Department of Radiotherapy, Torquay, UK


What is the role of tumour-associated bone marrow derived cells in the therapeutic response of tumours?

Year:

Session type:

Muhammad Babur, Majid Ali, Brian Telfer, Kaye Williams

University of Manchester, Manchester, UK


KU-0059436 plus radiation as first line therapy for glioblastoma multiforme: rationale and phase I clinical trial protocol

Year:

Session type:

Fiona Dungey1, Dana Loeser1, Anthony Chalmers2

1Genome Damage and Stability Centre, University of Sussex, Brighton, UK, 2Brighton and Sussex Medical School, Brighton, UK


In vitro and in vivo evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer

Year:

Session type:

Quang-De Nguyen1, Graham Smith1, Meg Perumal1, Matthias Glaser2, Euan A. Stronach3, Hani Gabra3, Eric O. Aboagye1

1Molecular Therapy Group, Imperial College London, London, UK, 2Hammersmith Imanet Limited, London, UK, 3Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Imperial College, London, UK


Imaging the biological activity of AKT-kinase-platinum drug combinations in vivo

Year:

Session type:

Meg Perumal, Quang-De Nguyen, Julius Leyton, Graham Smith, Euan Stronach, Hani Gabra, Eric Aboagye

Molecular Therapy/PET imaging, Imperial College, London, UK


Treatment of disseminated melanoma with 211At-methylene blue

Year:

Session type:

Eva Link

London, UK


Endogenous Prostate Apoptosis Response-4 (Par-4) inhibits in vitro growth and motility of prostate cancer cells

Year:

Session type:

Lin Ye, Malcolm Mason, Wen G. Jiang

Cardiff University School of Medicine, Cardiff, UK


Mechanisms of androgen receptor activation in advanced prostate cancer: differential coactivator recruitment and gene expression

Year:

Session type:

Greg Brooke, Malcolm Parker, Charlotte Bevan

Imperial College, London, UK


The effect of knockdown of ROCK II on the in vitro invasion and motility of PC3 prostate cancer cells

Year:

Session type:

Jane Lane, Tracey Amanda Martin, Wen Jiang

Cardiff University, Cardiff, UK


The role of Sox9 in prostate development and cancer

Year:

Session type:

Martin K. Thomsen, Amanda Swain

Section of Gene Function and Regulation, Institute of Cancer Research, London, UK


Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer with respect to the outcome of radical treatment

Year:

Session type:

Roy Vergis1, Catherine Corbishley2, Andrew Norman1, Jaclyn Bartlett1, Sameer Jhavar1, Michael Borre4, Sara Heeboll4, Alan Horwich1, Robert Huddart1, Vincent Khoo3, Ros Eeles1, Colin Cooper1, Matthew Sydes5, David Dearnaley1, Chris Parker1

1Institute of Cancer Research, Sutton, UK, 2St George's Hospital, Tooting, UK, 3Royal Marsden NHS Foundation Trust, Sutton, UK, 4Aarhus University Hospital, Skejby, Denmark, 5MRC, London, UK


Integration of ERG gene mapping and gene expression profiling identifies distinct categories of human prostate cancer

Year:

Session type:

Sameer Jhava1, Daniel Brewer1, Sandra Edwards1, Zsofia Kote-Jarai10, Gerhardt Attard1, Jeremy Clark1, Penny Flohr1, Alan Thompson3, Matthew Parker1, Ulf-Hakan Stenman4, Tania Marchbank5, Raymond Playford5, Cyril Fisher6, Gyula Kovacs7, Cathy Corbishley8, Andy Norman2, Johann De-Bono2, Anders Bjartell9, Rosalind Eeles10, Colin Cooper1

1Institute of Cancer Research, Male Urological Cancer Research Centre, Molecular Carcinogenesis, Sutton, UK, 2Royal Marsden NHS Foundation Trust, Sutton, UK, 3Department of Academic Urology, The Royal Marsden NHS Trust Foundation Hospital, London, UK, 4Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland, 5Institute of Cell and Molecular Science, Barts and The London School of Medicine, London, UK, 6Department of Histopathology, The Royal Marsden NHS Trust Foundation Hospital, London, UK, 7Laboratory of Molecular Oncology, Medical Faculty, Reprecht-Karls-University, Heidelberg, Germany, 8Department of Cellular Pathology, SGHNHSFT, London, UK, 9Department of Urology, University Hospital Malmo, Malmo, Sweden, 10Institute of Cancer Research, Male Urological Cancer Research Centre, Genetics, Sutton, UK


Circulating Tumor Cell (CTC) counts as intermediate endpoints in Castration-Resistant Prostate Cancer (CRPC): a single centre experience

Year:

Session type:

David Olmos1, Gerhart Attard1, Alison Reid1, Joana Moreira2, Juliet Dukes2, Joo Ern Ang1, Hendrik-Tobias Arkenau1, Roger A'Hern2, Emilda Thompson1, Craig Carden1, Chris Parker1, Johann de Bono1

1The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 2The Institute of Cancer Research, Sutton, Surrey, UK


Prostate tumours with PTEN loss detected by fluorescent in situ hybridisation (FISH) have a worse clinical outcome and are enriched for ETS gene alterations

Year:

Session type:

Alison Reid1, Gerhardt Attard1, Jeremy Clark1, Roy Vergis2, Sara Heeboll3, Daniel Brewer1, Chris Parker2, Johann De-Bono2, Michael Borre3, Colin Cooper1

1Institute of Cancer Research, Sutton, Surrey, UK, 2Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 3Aarhus University Hospital, Skejby, Denmark


Identification of candidate biomarkers associated with prostate cancer progression using a proteomic 8-plex iTRAQ approach

Year:

Session type:

Adam Glen, Chee S. Gan, Freddie C. Hamdy, Colby L. Eaton, Simon S. Cross, Phillip C. Wright, Ishtiaq Rehman

University of Sheffield, Sheffield, UK


Psychological distress and prostate specific antigen levels in men with and without prostate cancer

Year:

Session type:

Emma Turner1, Athene Lane1, Chris Metcalfe1, Liz Down1, Freddie Hamdy3, David Neal2, Jenny Donovan1, Kavita Vedhara1

1University of Bristol, Bristol, UK, 2University of Cambridge, Cambridge, UK, 3University of Sheffield, Sheffield, UK


Rectal contouring variability in patients treated with radical radiotherapy for prostate carcinoma and its impact on rectum dose-volume histograms: pilot study

Year:

Session type:

Jacqueline Martin, Peter Kirkbride

Weston Park Hospital, Sheffield, UK


Preclinical development strategy for regulatory approval of a Phase I Trial of 99mTc Demobesin-4 (99mTc DB4) for prostate cancer imaging

Year:

Session type:

Steve Colebrook1, Paul Jones1, Karen Owen1, Rob Williams1, Steve Mather2, Norbert Avril2

1Cancer Research UK, Drug Development Office, London, UK, 2St Bartholomew's Hospital, Department of Nuclear Medicine, London, UK


A prospective study of clinically significant fatigue (CSF) after prostate brachytherapy (PB)

Year:

Session type:

Dawn Storey1, Duncan McLaren1, Rita O'Dea1, Sheila Liggat1, Morven Shipway1, John Smyth2, Michael Sharpe2

1Edinburgh Cancer Centre, Edinburgh, Mid Lothian, UK, 2University of Edinburgh Cancer Research Centre, Edinburgh, Mid Lothian, USA


Salvage radiotherapy for biochemical relapse of prostate cancer after prostatectomy

Year:

Session type:

Jacob S Tanguay1, Laura Petit3, Helen Sharman1, Jawaher Ansari1, Nellie Cheah1, Kate Yates2, Naryanan Srihari3, Andrew Stockdale2, Nicholas James1

1University Hospital Birmingham, Birmingham, UK, 2University Hospital Coventry and Warwick, Coventry, UK, 3Royal Shrewsbury Hospital, Shrewsbury, UK


Monitoring prostate cancer progression with Diffusion Weighted Imaging: variability of perfusion and diffusion components of the Apparent Diffusion Coefficient

Year:

Session type:

Veronica Morgan, Sophie Riches, Nicholas vanAs, Christopher Parker, Nandita deSouza

Institute of Cancer and Royal Marsden NHS Foundation Trust, Sutton, UK


Automated [11C]acetate synthesizer – simple way to reliable GMP compliant manufacture of prostate cancer PET imaging radiotracer

Year:

Session type:

Dmitry Soloviev2, Jozef Comor3, Gerd Beyer4, Franklin Aigbirhio1

1Wolfson Brain Imaging Centre, Cambridge University, Cambridge, UK, 2Cambridge Research Institute, Cancer Research UK, Cambridge, UK, 3Vinca Institute, Belgrade, Serbia, 4Isotope Technologies Dresden GmbH (ITD), Dresden, Germany


Computer modelling of prostate gland deformation for image-guided biopsy and cancer therapies

Year:

Session type:

Dean Barratt1, Yipeng Hu1, Dominic Morgan1, Hashim Ahmed1, Doug Pendse1, Mahua Sahu1, Clare Allen2, David Hawkes1, Mark Emberton1

1University College London, London, UK, 2University College Hospital, London, UK


Upper gastrointestinal cancer laparoscopy and endoluminal ultrasound staging audit across five cancer networks

Year:

Session type:

Diana Bailey, Mark Vipond

South West Public Health Observatory, Salisbury, UK


An association study of TGFB1 gene variants with post-radiotherapy breast shrinkage: preliminary results of the RAPPER study

Year:

Session type:

Gillian C. Barnett1, Neil G. Burnet1, Charlotte E. Coles1, Caroline Baynes2, Serena Scollen2, Paul D.P. Pharoah2, Elliott Rebecca3, Catharine M.L. West3, Patricia Harrington2, Jennifer Wilkinson1, Margaret Moody1, Carol McQuade1, Gordon C. Wishart1, Alison M. Dunning2

1Addenbrooke's Hospital, Cambridge, UK, 2Strangeways Research Laboratory, Cambridge, UK, 3University of Manchester, Manchester, UK


IMPORT HIGH: introduction of image guided breast radiotherapy via a national breast trial

Year:

Session type:

Jenny Titley1, Judith Bliss1, Charlotte Coles2, Ellen Donovan2, Philip Evans1, Jo Haviland1, Mark Sydenham1, John Yarnold1, IMPORT Trial Management Group3

1Institute of Cancer Research, Sutton, UK, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 3NHS, National, UK


Exposure to sunlight and prostate cancer

Year:

Session type:

Rebecca Gilbert1, Chris Metcalfe1, Steven Oliver3, David Whiteman2, Chris Bain4, Andy Ness5, Richard Martin1

1Department of Social Medicine, University of Bristol, Bristol, UK, 2Division of Population Studies and Human Genetics, Queensland Institute of Medical Research, Queensland, Australia, 3Department of Health Sciences, University of York, Bristol, UK, 4School of Population Health, The University of Queensland, Queensland, Australia, 5Department of Oral and Dental Science and Department of Social Medicine, University of Bristol, Bristol, UK


Incidence, diversity and clinical relevance of ETV1 translocations in human prostate cancer

Year:

Session type:

Jeremy Clark1, Gerhardt Attard2, Laurence Ambroisine3, Ian Mills4, Gabrielle Fisher3, Penny Flohr1, Alison Reid1, Sandra Edwards1, Gyula Kovacs5, Dan Berney6, Chris Foster7, CE Massie4, Anne Fletcher1, Johann de Bono1, P Scardino1, J Cuzick3, Colin Cooper1

1lnstitute of Cancer Research, Sutton, UK, 2The Royal Marsden NHS Trust Foundation Hospital, Sutton, UK, 3Cancer Research UK Centre for Epidemiology, London, UK, 4Uro-Oncology Research Group,, Cambridge, UK, 5Ruprecht-Karls-Universitat, Heidelberg, Germany, 6The Orchid Tissue Laboratory, London, UK, 7The University of Liverpool, Liverpool, UK, 8Department of Pathology, New York, USA


Identification of multiple novel prostate cancer predisposition loci

Year:

Session type:

Ros Eeles1, Zsofia Kote-Jarai1, Douglas Easton2, Janet Stanford3, Elaine Ostrander4, Johanna Schleutker5, Sue Ingles6, Daniel Schaid7, Stephen Thibodeau7, Thilo Dork8, David Neal/ProtecT Group9, Walter Vogel10, Michelle Guy1, Kenneth Muir11, Mary-Anne Kedda12, Esther John13, Graham Giles14, Will Foulkes15, Ali Amin Al Olama2, The PRACTICAL/UKGPCS Group1

1The Institute of Cancer Research, Sutton, UK, 2Strangeways Laboratory, Cambridge, UK, 3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, 4National Human Genome Research Institute, National Institutes of Health, Bethesda MD, USA, 5Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland, 6Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles CA, USA, 7Mayo Clinic, Minnesota, USA, 8Hannover Medical School, Hannover, Germany, 9Surgical Oncology, Cambridge Research Institute, Cambridge, UK, 10Institut für Humangenetik, Ulm, Germany, 11University of Nottingham, Nottingham, UK, 12School of Public Health and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, 13Northern California Cancer Center, Fremont, California, USA and Stanford University School of Medicine, Stanford, California, USA, 14Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia, 15McGill University, Montreal, Canada


High frequency of t(4;6) translocation and 6q15 deletion in prostate cancer

Year:

Session type:

Ling Shan, Sharon James, Rafael Yanez-Munoz, Yong-Jie Lu

Queen Mary college, London, UK


Improving trial conduct through a new site monitoring and review process (SMART): experience from the ProtecT study

Year:

Session type:

J Athene Lane1, Susan Bonnington2, Teresa Lennon3, Peter Holding7, Amanda Jones4, C Elizabeth Salter5, David Neal6, Freddie Hamdy7

1University of Bristol, Bristol, UK, 2Leicester General Hospital, Leicester, UK, 3Freeman Hospital, Newcastle, UK, 4University Hospital of Wales, Cardiff, UK, 5Bristol Urological Institute, Bristol, UK, 6Addenbrooke's Hospital, Cambridge, UK, 7University of Sheffield, Sheffield, UK


Diethylstilboestrol is active in docetaxel treated androgen independent prostate cancer

Year:

Session type:

Richard Cox, Santhanam Sundar

Nottingham City Hospital, Nottingham, UK


Efficacy of docetaxel re-treatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pre-treated with docetaxel

Year:

Session type:

Jawaher Ansari1, Syed Anwer Hussain1, Anjali Zarkar1, Jacob S Tanguay1, Julie Bliss2, John Glaholm1

1University Hospital Birmingham NHS Trust, Birmingham, UK, 2Good Hope Hospital, Birmingham, UK


Source data verification in a multi-centre randomised controlled trial: the ProtecT study

Year:

Session type:

Michael Davis1, Liz Down1, Athene Lane1, Peter Holding2, David Neal3, Freddie Hamdy2, Jenny Donovan1

1University of Bristol, Bristol, UK, 2University of Sheffield, Sheffield, UK, 3University of Cambridge, Cambridge, UK


Combination of finasteride with the chemopreventive agent resveratrol, decreases proliferative capacity of prostate cancer cells at physiologically achievable doses

Year:

Session type:

Lynne Howells, Emma Blake, Karen Brown

University of Leicester, Leicester, UK


NO-sulindac inhibits the hypoxia response of prostate cancer cells via the Akt signalling pathway

Year:

Session type:

Grant Stewart, Jyoti Nanda, Gordon Brown, Antony Riddick, James Ross, Fouad Habib

University of Edinburgh, Edinburgh, UK


A single institution’s experience of over 200 cases of robotic-assisted radical prostatectomy

Year:

Session type:

Naomi Sharma, Nimish Shah, David Neal

Addenbrooke's Hospital, Cambridge, UK


Functional wellbeing and lower-limb skeletal muscle function in prostate cancer patients on androgen deprivation therapy (ADT)

Year:

Session type:

Liam Bourke, Helen Crank, Amanda Daley, Derek Rosario, John Saxton

1Sheffield Hallam University, Sheffield, UK, 2Sheffield Hallam University, Sheffield, UK, 3University of Birmingham, Birmingham, UK, 4University of Sheffield, Sheffield, UK, 5Sheffield Hallam University, Sheffield, UK


Modulation of androgen receptor activity in prostate cancer progression and therapy

Year:

Session type:

Greg Brooke, Deepa Chotai, Alwyn Dart, Simon Gamble, Derek Lavery, Sue Powell, Vikash Reebye, Charlotte Bevan

Imperial College London, London, UK


Development of a stereo image guidance system to assist robotic surgery of prostate cancer using augmented reality

Year:

Session type:

Dongbin Chen, Erik Mayer, Justin Vale, Anne Anstee, Ara Ara Darzi, Guang-Zhong Yang, Eddie Edwards

Imperial College, London, UK


siRNA target selection using machine learning techniques: genes implicated in aggressive prostate cancer

Year:

Session type:

Matthew Parker1, Colin Campbell2, Luke Carrivick2, Colin Cooper1

1The Institute of Cancer Research, Sutton, UK, 2University of Bristol, Bristol, UK


Genetic susceptibility to prostate cancer due to rare mutations in genes in the DNA repair pathway

Year:

Session type:

Zsofia Kote-Jarai1, Sarah Jugurnauth1, Shani Mulholland1, Stephen Edwards1, Michelle Guy1, Daniel Leongamornlert1, Nayanta Sodha1, Lynn O'Brien1, Rosmary Wilkinson1, Audrey Ardern-Jones2, Amanda Hall2, David Dearnaley2, Keneth Muir3, Aritaya Lophatananon3, The UK Genetic Prostate Cancer Study Collaborators1, The British Association of Urological Surgeon's Section of Oncology2, Douglas Easton4, Rosalind Eeles1

1The Institute of Cancer Research, Sutton/Surrey, UK, 2The Royal Marsden NHS Foundation Trust, Sutton/Surrey, UK, 3University of Notthingham, Notthingham, UK, 4CR-UK Genetic Epidemiology Unit, Cambridge, UK